Filter
Incyte: Bad News Buy?
John McCamant Image John McCamant

Incyte (INCY) and their partner Eli Lilly (LLY) have received a Complete Response Letter (CRL) from the FDA delaying the…

Tickers: INCY
PRA Health: Clinical Profits
Timothy Lutts Image Timothy Lutts

As a growth investor, I’m always on the lookout for companies with revolutionary new products or services, notes …

Tickers: PRAH
Activists Eyes Bristol-Myers
Stephen Leeb Image Stephen Leeb

The news that activist investor Carl Icahn has taken a position in Bristol-Myers Squibb (BMY) is fueling takeover spec…

 
Adamas Targets Parkinson's and MS
Bret Jensen Image Bret Jensen

Adamas Pharmaceuticals (ADMS) is a drug improvement company that develops chrono-synchronous therapies for patients aff…

Tickers: ADMS
Invitae: A Menu of Genes
Briton Ryle Image Briton Ryle

Invitae Corp (NVTA) first earned a spot on our Top 10 list of best buys back in February, and it hasn’t stopped …

 
The Cheap Investor
Bill Mathews Image Bill Mathews

Bovie Medical Corporation (BVX) is a leading maker of medical devices and supplies as well as the developer of J- Plasm…

 
Bioverativ: Spin-Off Targets Hemophilia
George Putnam Image George Putnam

Bioverativ (BIVV), spun off from biotech giant Biogen (BIIB) in February, focuses on treating hemophilia, a relatively…

Tickers: BIVV
Esperion: "Hitting on all Cylinders"
John McCamant Image John McCamant

Esperion Therapeutics (ESPR) and their experienced cardiovascular development team are hitting on all cylinders, obser…

Tickers: ESPR
Vertex: Still a "Top Pick"
Crista Huff Image Crista Huff

In MoneyShow's annual Top Picks report in January, Crista Huff chose Vertex Pharmaceuticals (VRTX) as her favorite inves…

Tickers: SNI
Express Scripts: The Right Prescription?
Charles Mizrahi Image Charles Mizrahi

We recently added Express Scripts Holdings (ESRX) to the Prime Time Portfolio; the company is the largest pharmacy ben…

Tickers: ESRX
 

Expert Investing and Trading Advice

If you’re an independent investor, trader or financial advisor in search of relevant, reliable and timely financial advice, you’ve come to the right place! Before you pave your own path to profits, you need to arm yourself with state-of-the-art tools, a powerful skill set and an absolute understanding of the markets. Guided by the principle that “knowledge is power,” for more than three decades MoneyShow has been carefully handpicking the resources that perceptive investors and traders need to succeed.

 

MoneyShow.com has over 1,500 contributors who are among the most respected and trusted names in the financial field. These experts bring daily market insights, stock picks and trading tips, and actionable advice regarding the day’s hottest topics to our MoneyShow.com readers.

Investment Education to Help You Succeed

MoneyShow makes pertinent articles available on its website to help you become a more informed, knowledgeable and successful investor. Our readers get exclusive access to ideas, analyses and long- and short-term investment strategies from the world’s leading market experts — expert authors with proven track records of successful investing.

Subscribe to E-Newsletters

Whether you’re an independent investor or trader or a seasoned pro looking for sophisticated strategies, you’ll find useful advice — from stocks, bonds, mutual funds and ETFs to currencies, futures and global investing. Our articles offer you the actionable advice you need to achieve your financial goals.